Overview

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
0
Participant gender:
All
Summary
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Sertraline
Criteria
Inclusion Criteria:

- Outpatients with DSM-IV major depressive disorder

Exclusion Criteria:

- Women of child bearing potential